Graig Suvannavejh
Stock Analyst at Mizuho
(4.49)
# 270
Out of 5,129 analysts
171
Total ratings
56.25%
Success rate
19.35%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMX Immix Biopharma | Initiates: Outperform | $14 | $6.82 | +105.28% | 1 | Feb 9, 2026 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $205 | $77.98 | +162.89% | 1 | Jan 7, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $11.64 | -57.04% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $37.70 | +43.24% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $169.27 | +14.61% | 2 | Dec 2, 2025 | |
| INSM Insmed | Maintains: Outperform | $196 → $256 | $146.80 | +74.39% | 12 | Dec 1, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $36.87 | +24.76% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $65.09 | +53.63% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $10.00 | +130.00% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $79.51 | -29.57% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $31.72 | +45.04% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $185.48 | +8.91% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $21.89 | -13.20% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.55 | +158.06% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.40 | +7,409.39% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.90 | +84.21% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.01 | +66.39% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $4.98 | +100.80% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $19.03 | -42.20% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $13.06 | +99.08% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.24 | -43.82% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.98 | +0.06% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.40 | +442.74% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $7.44 | +894.62% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.18 | -54.13% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $98.84 | -64.59% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $22.76 | -64.85% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $66.00 | -13.64% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $28.64 | -82.54% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $9.78 | +247.65% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.37 | +170.01% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $30.13 | +2.89% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $13.10 | +2,800.76% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.72 | +176.97% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $26.28 | +36.99% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $34.12 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $2.09 | +1,674.58% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $163.91 | -21.91% | 1 | Sep 14, 2020 |
Immix Biopharma
Feb 9, 2026
Initiates: Outperform
Price Target: $14
Current: $6.82
Upside: +105.28%
Palvella Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $205
Current: $77.98
Upside: +162.89%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $11.64
Upside: -57.04%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $37.70
Upside: +43.24%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $169.27
Upside: +14.61%
Insmed
Dec 1, 2025
Maintains: Outperform
Price Target: $196 → $256
Current: $146.80
Upside: +74.39%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $36.87
Upside: +24.76%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $65.09
Upside: +53.63%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $10.00
Upside: +130.00%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $79.51
Upside: -29.57%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $31.72
Upside: +45.04%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $185.48
Upside: +8.91%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $21.89
Upside: -13.20%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.55
Upside: +158.06%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.40
Upside: +7,409.39%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.90
Upside: +84.21%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.01
Upside: +66.39%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $4.98
Upside: +100.80%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $19.03
Upside: -42.20%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $13.06
Upside: +99.08%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.24
Upside: -43.82%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.98
Upside: +0.06%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.40
Upside: +442.74%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.44
Upside: +894.62%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.18
Upside: -54.13%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $98.84
Upside: -64.59%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $22.76
Upside: -64.85%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $66.00
Upside: -13.64%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $28.64
Upside: -82.54%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $9.78
Upside: +247.65%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.37
Upside: +170.01%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $30.13
Upside: +2.89%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $13.10
Upside: +2,800.76%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.72
Upside: +176.97%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $26.28
Upside: +36.99%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $34.12
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $2.09
Upside: +1,674.58%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $163.91
Upside: -21.91%